LEADER 03168nam0 2200577 i 450 001 VAN00123739 005 20240806100814.368 017 70$2N$a9783319515007 100 $a20191001d2017 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 200 1 $aOperations Research, Engineering, and Cyber Security$eTrends in Applied Mathematics and Technology$fNicholas J. Daras, Themistocles M. Rassias editors 210 $aCham$cSpringer$d2017 215 $axi, 422 p.$cill.$d24 cm 410 1$1001VAN00067197$12001 $aSpringer optimization and its applications$1210 $aBerlin [etc.]$cSpringer$d2006-$v113 500 1$3VAN00235864$aOperations Research, Engineering, and Cyber Security$91562234 606 $a03D25$xRecursively (computably) enumerable sets and degrees [MSC 2020]$3VANC024512$2MF 606 $a11Uxx$xConnections of number theory and logic [MSC 2020]$3VANC024437$2MF 606 $a26D15$xInequalities for sums, series and integrals [MSC 2020]$3VANC019776$2MF 606 $a31A10$xIntegral representations, integral operators, integral equations methods in two dimensions [MSC 2020]$3VANC029359$2MF 606 $a44A10$xLaplace transform [MSC 2020]$3VANC019854$2MF 606 $a45Pxx$xIntegral operators [MSC 2020]$3VANC020260$2MF 606 $a46E30$xSpaces of measurable functions (Lp-spaces, Orlicz spaces, Köthe function spaces, Lorentz spaces, rearrangement invariant spaces, ideal spaces, etc) [MSC 2020]$3VANC028800$2MF 606 $a47A07$xForms (bilinear, sesquilinear, multilinear) [MSC 2020]$3VANC033668$2MF 606 $a47G10$xIntegral operators [MSC 2020]$3VANC029358$2MF 606 $a68R10$xGraph theory (including graph drawing) in computer science [MSC 2020]$3VANC023623$2MF 606 $a94C30$xApplications of design theory to circuits and networks [MSC 2020]$3VANC023606$2MF 610 $aAir Defense Systems and Detection Theory$9KW:K 610 $aAlgorithmic complexity$9KW:K 610 $aCyber-warfare$9KW:K 610 $aData to Decisions$9KW:K 610 $aDecision Models$9KW:K 610 $aEngineered Resilient Systems$9KW:K 610 $aMathematical Modeling and Simulation$9KW:K 610 $aMilitary Operations Research$9KW:K 610 $aPrediction Theory$9KW:K 620 $aCH$dCham$3VANL001889 702 1$aDaras$bNicholas J.$3VANV080641 702 1$aRassias$bThemistocles M.$f1951- $3VANV041928 712 $aSpringer $3VANV108073$4650 790 1$aDaras, N.J.$zDaras, Nicholas J.$3VANV234323 790 1$aDaras, N. J.$zDaras, Nicholas J.$3VANV234324 801 $aIT$bSOL$c20241115$gRICA 856 4 $uhttp://doi.org/10.1007/978-3-319-51500-7$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$1IT-CE0120$2VAN08 912 $fN 912 $aVAN00123739 950 $aBIBLIOTECA DEL DIPARTIMENTO DI MATEMATICA E FISICA$d08DLOAD e-book 0828 $e08eMF828 20191001 996 $aOperations Research, Engineering, and Cyber Security$91562234 997 $aUNICAMPANIA LEADER 04386nam 2200673Ia 450 001 9910968082403321 005 20240516122658.0 010 $a9781608051328 010 $a1608051323 035 $a(CKB)2670000000067026 035 $a(EBL)864213 035 $a(OCoLC)819594352 035 $a(SSID)ssj0000494865 035 $a(PQKBManifestationID)11326006 035 $a(PQKBTitleCode)TC0000494865 035 $a(PQKBWorkID)10453020 035 $a(PQKB)11295234 035 $a(MiAaPQ)EBC864213 035 $a(Au-PeEL)EBL864213 035 $a(CaPaEBR)ebr10447992 035 $a(DE-B1597)732022 035 $a(DE-B1597)9781608051328 035 $a(EXLCZ)992670000000067026 100 $a19990506d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAnastin and malignant gliomas /$feditor, Thomas C. Chen ; co-editor, Marc Chamberlain 205 $a1st ed. 210 $a[S.l.] $cBentham e Books$d[2011] 215 $a1 online resource (219 p.) 225 0 $aControversies in neuro-oncology 300 $aDescription based upon print version of record. 311 08$a9781608055197 311 08$a1608055191 320 $aIncludes bibliographical references and indexes. 327 $a01 Cover Page.pdf; 02 Title Page; 03 eBooks End User License Agreement-Website; 04 table of contents; 05 Foreword; 06 PREFACE-Avastin; 07 Contributors; 08 Part 1 BASIC SCIENCE AND RATIONALE; 09 Ch-1; 10 Part 2; 11 Ch-2 Desjardins-Avastin-recurrent-chen; 12 Ch-3 kreisl-Avastin_and_Mailgnant_Gliomas_-_Is_there_a_role[1]-chen; 13 Ch-4 GutinRT-_bev_review_FI_PG_9-22[1]-chen; 14 Ch-5 norden_controversies_6-19-09[1]-chen; 15 Part 3; 16 Ch-6 Reardon_chapter_8[1].29; 17 Ch-7 Mehta-radiationControversies_in_Neuro-Avastin-final[1]-chen 327 $a18 Ch-8 Gilbert-Bevacizumab_and_Malignant_Glioma_final_version_9-14-09[1]-Gilbert-chen19 Part 4; 20 Ch-9 Schiff-Avastin toxicityFinal-Bevacizumab_Toxicity_in_Glioblastoma_with_DS_edits_090109-for_review_11[1]-chen corrected; 21 Ch-10 Rogers Chapter_-_Avastin_and_AC_-_Chamberlain_11-2-09__3_[2]-Chen; 22 Part 5; 23 Ch-11 Raizer- AvastinFinal__2_[1]-chen; 24 Part 6; 25 Ch-12 POPE_GBM_Avastin_Imaging[1]-chen; 26 Ch-13 Butowski-radiographic responses 2-chen; 27 Ch-14 Imaging Responses of Bevacizuma; 28 Ch-15 HENSON091509cleanref[1]-chen; 29 Part 7; 30 Ch-16 Aghi-_Avastin_v2[1]-Chen 327 $a31 Ch-17 Vogelbaum-Surgical Implications-Avastin_Final[1]-chen32 Part 8; 33 Ch-18 chamberlain-BevNovelApplications_8_6_09[1]-chen; 34 Ch-19 Levin-Radiation_necrosis-082509-Final[1]-chen; 35 Ch-20 chamberlain-salvage-chen; 36 Part 9; 37 Ch-21 StuppBev_rec_glioma__final[1]-chen; 38 Ch-22 van den Bent-Avastin in Europe-chen; 39 Ch-23 Avastin_Weller_2009-6-30[1]-chen; 40 Ch-24 Wick European pers-chen; 41 Part 10; 42 Ch-25 Sunitinib_ebook_chapter___B_Neyns[1]-chen; 43 Ch-26 nabors-cilengitide-chen; 44 Ch-27 SorafenibChapter_FINAL[2]-chen; 45 Ch-28 Wen-VEGF-trap_8-14-09_FINAL[1]-chen 327 $a46 Ch-29 Batchelor-Gerstner-Dietrich-Cediranib-09-12-09[1]-chen47 Part 11 Conclusion; 48 Ch-30 Gu Development_of_Bevacizumab[1][1]-chen; 49 Author Index -Avastin; 50 Index-final-chen 330 $aNeuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small scale phase I/II trials performed have proved to be inconclusive because of the limited number of patients involved. As a result, many controversies exist in neuro-oncology drug development for which a forum does not exist. This ebook presents a detailed account on the use of avastin in treating cancer patients. A discussion on clinical experiences and the controversial debate among researchers of ava 410 0$aControversies in Neuro-Oncology, 1 606 $aGliomas 606 $aBevacizumab 615 0$aGliomas. 615 0$aBevacizumab. 676 $a616.8 700 $aChen$b Thomas C, $4aut$4http://id.loc.gov/vocabulary/relators/aut$01800194 701 $aChen$b Thomas C$01800194 701 $aChamberlain$b Marc C$01800195 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910968082403321 996 $aAnastin and malignant gliomas$94344839 997 $aUNINA